Evidence map›Paper›PMID 42610933›Full record

ArticleDiabetes2026

Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals With Type 1 Diabetes.

Elizabeth R Flammer, Lauren E Higdon, Srinath Sanda, Todd M Brusko, Timothy J Garrett, Heba M Ismail

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Elizabeth R FlammerDepartment of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL.
Lauren E HigdonImmune Tolerance Network, Biomarker and Discovery Research, San Francisco, CA.
Srinath SandaImmune Tolerance Network, Biomarker and Discovery Research, San Francisco, CA.
Todd M BruskoDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0003-2878-9296
Timothy J GarrettDepartment of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL.ORCID 0000-0003-1623-009X
Heba M IsmailDepartment of Pediatrics, School of Medicine, Indiana University, Indianapolis, IN.ORCID 0000-0003-0102-0030

Funding

Division of Diabetes, Endocrinology, and Metabolic Diseases NO1-AI-15416National Institute of Allergy and Infectious Diseases of the National Institutes of Health UM1AI109565
6 · The paper itself

Abstract

article highlightsWe believed that baseline serum metabolomic signatures can predict response to immunotherapies to identify which individuals will benefit most from treatment. We aimed to identify whether baseline serum metabolomic profiles can distinguish responders from nonresponders to teplizumab. Fifteen metabolites were identified as significantly different. Our findings suggest that baseline serum metabolomic signatures could be used to predict which newly diagnosed type 1 diabetes patients will respond to teplizumab, enabling more personalized treatment decisions.

Identifiers

PMID42610933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.